Who Owns Novo Nordisk Company?

Who Owns Novo Nordisk?

Novo Nordisk is mainly owned by the Novo Nordisk Foundation, which controls a large voting stake. The shares also trade publicly in Copenhagen and New York, so outside investors hold part of the company too.

The foundation setup gives Novo Nordisk long-term control and strong influence over strategy. For a quick scan of the business setup, see Novo Nordisk Balanced Scorecard.

Novo Nordisk was built from Danish insulin roots, then shaped by a foundation-led ownership model that still defines Novo Nordisk ownership today. If you ask who owns Novo Nordisk, the short answer is public shareholders plus a dominant long-term block through Novo Holdings A/S.

Founding roots

who founded Novo Nordisk company traces back to Danish insulin pioneers in the early 1900s. That origin matters because the business began as a science-led project, not a financial play.

Early ownership model

Early Novo Nordisk founding family ownership was not built like a modern venture-backed firm. Control moved into a foundation structure that still shapes Novo Nordisk corporate structure today.

Who controls Novo Nordisk

In 2025, Novo Holdings A/S, for the Novo Nordisk Foundation, held about 28% of capital and roughly 77% of voting rights. That makes the foundation block the clear anchor in Novo Nordisk ownership structure explained.

Share class split

Novo Nordisk A shares and B shares create a dual-class setup. So Novo Nordisk share classes explained is simple: economic ownership is broader than voting control.

Public market base

Yes, is Novo Nordisk publicly traded. The rest of Novo Nordisk shareholders are institutions, index funds, pension funds, and retail investors.

Ownership meaning

The answer to who is the largest shareholder of Novo Nordisk is the foundation-linked block. That patient owner profile supports trust in a drug maker with long R and D cycles.

So, how is Novo Nordisk owned? The public owns most of the float economically, but the Novo Nordisk Foundation, through Novo Holdings A/S, keeps the key vote. That is why Novo Nordisk stock ownership looks dispersed on paper but concentrated in control, and it is also why Mission, Vision & Core Values of Novo Nordisk helps explain the governance logic behind the business.

Key ownership facts

As of 2025, Novo Nordisk major shareholders are led by the foundation-linked block, not a short-term sponsor. Public holders still matter, but they do not set control.

• Foundation-linked control: 77% of votes
• Economic stake: about 28% of capital
• Public holders: institutions, funds, retail
• Owner profile: philanthropic and science-linked

Novo Nordisk SWOT Analysis

• Organized to Save Time on Analysis
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Novo Nordisk ownership changed in three key steps: the 1989 merger built a larger global drug business, public listings added market discipline, and the foundation-controlled share structure kept long-term control in place. That mix still shapes who owns Novo Nordisk, who controls Novo Nordisk, and how investors read the brand.

Novo Nordisk ownership structure explained starts with dual-class shares and foundation control. That means Novo Nordisk A shares and B shares do not carry the same vote power, so economic ownership and control are not identical. For investors asking is Novo Nordisk publicly traded or does the Danish government own Novo Nordisk, the answer is clear: it is publicly traded, and control sits with the foundation-linked structure, not the Danish state. The model helps explain why many Novo Nordisk institutional investors own the stock for cash flow and liquidity, but have less control than their stake suggests. For more context on strategy, see Growth Strategy of Novo Nordisk.

How ownership shapes trust

The ownership model signals long-term mission, not just quarterly returns. In a drug business, that matters because patients and payers watch pricing, supply, safety, and ethics closely.

• Foundation control supports stable strategy
• Dual-class shares limit outside control
• Public listings add disclosure and checks
• 2024 revenue reached DKK 290.4 billion

Novo Nordisk Ansoff Matrix

• Structured to Support Better Decisions
• Effortlessly Communicate Your Business Strategy
• Investor-Ready Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Novo Nordisk's board sits at the center of control, but real voting power is concentrated in Novo Nordisk Foundation-backed ownership through Novo Holdings A/S. In 2025, the board and executive team also showed they can act fast on leadership changes, with Lars Fruergaard Jørgensen set to step down and Maziar Mike Doustdar named as CEO.

The Novo Nordisk ownership model is a clear case of how is Novo Nordisk owned: the dual-class share structure gives A shares more votes than B shares, so Novo Nordisk stock ownership is not the same as voting power. That is why who controls Novo Nordisk is better answered by looking at votes, not just shares. For a wider view of the business engine, see Revenue Streams & Business Model of Novo Nordisk.

Who really controls Novo Nordisk

The board oversees the big choices, but the foundation-backed vote decides who sits on it. That is the core of Novo Nordisk ownership structure explained.

• Novo Nordisk Foundation is the main voting force
• Novo Holdings A/S channels control
• Board handles capital and succession
• CEO runs launches and operations

Novo Nordisk shareholders with B shares can own a large slice of the equity and still have limited say on elections, which is why Novo Nordisk share classes explained matters for any Novo Nordisk stock owner details review. In plain terms, is Novo Nordisk publicly traded yes, but public trading does not mean public control. The company's 2025 leadership change also showed that foundation-backed governance can move decisively when performance or credibility demands it.

Novo Nordisk Balanced Scorecard

• Clean, Modern, and Easy to Present
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Novo Nordisk ownership remained unusually stable in 2025: the Novo Nordisk Foundation, through Novo Holdings, kept its controlling role while the stock stayed publicly traded. That mix matters because it supports long R&D, supply planning, and brand trust, but it also means minority Novo Nordisk shareholders have limited control.

For investors asking who owns Novo Nordisk, the answer is simple: the Danish foundation structure is the anchor, while public shareholders supply market capital and trading liquidity. That setup has supported steady cash returns, big obesity and diabetes bets, and a lower risk of short-term strategic drift, but it also makes governance quality a key part of the investment case.

Foundation Control

The Novo Nordisk Foundation-backed structure gives Novo Nordisk long-term control. It also helps explain why the company can fund multi-year R&D without chasing short-term market moves.

Public Market Discipline

Because Novo Nordisk is publicly traded, it still faces quarterly scrutiny and disclosure rules. That mix is central to Novo Nordisk stock ownership and brand credibility.

Share Classes

Novo Nordisk A shares and B shares explain who controls Novo Nordisk. The A shares carry far more voting power, so economic ownership and control are not the same thing.

Owner Oversight in 2025

The 2025 CEO change showed that Novo Nordisk major shareholders can intervene when growth and market confidence weaken. That matters for anyone studying Novo Nordisk ownership structure explained in practice.

In 2020 to 2025, Novo Nordisk kept expanding in diabetes and obesity, returned cash through dividends and buybacks, and stayed one of Europe's most watched healthcare names. The Competitors Landscape of Novo Nordisk helps place that ownership model beside the company's competitive pressure and investor base.

Institutional Holders

Novo Nordisk institutional investors add liquidity and price discipline. They do not control the firm, but they shape how the market reads execution and governance.

Control Versus Credibility

Yes, Novo Nordisk founding family ownership is indirect, not personal. The real test is whether the governance setup keeps trust high while protecting minority holders.

Novo Nordisk VRIO Analysis

• Designed for Fast Business Analysis
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔